Background Coronary stenting appears to provide more predictable immediate results and lower rates of restenosis than conventional balloon angioplasty for selected lesion types, but its hospital costs are significantly higher. This study was designed to evaluate the potential cost-effectiveness of Palmaz-Schatz coronary stenting relative to conventional balloon angioplasty for the treatment of patients with symptomatic, single-vessel coronary disease.
Methods and Results We developed a decision-analytic model to predict quality-adjusted life expectancy and lifetime treatment costs for patients with symptomatic, single-vessel coronary disease treated by either Palmaz-Schatz stenting (PSS) or conventional angioplasty (PTCA). Estimates of the probabilities of overall procedural success (PTCA, 97%; PSS, 98%), abrupt closure requiring emergency bypass surgery (PTCA, 1.0%; PSS, 0.6%), and angiographic restenosis (PTCA, 37%; PSS, 20%) were derived from review of the literature published as of September 1993. Procedural costs were based on the true economic (ie, variable) costs of each procedure at Boston's Beth Israel Hospital. On the basis of these data, coronary stenting was estimated to result in a higher quality-adjusted life expectancy than conventional angioplasty but to incur additional costs as well. Compared with conventional angioplasty, stenting had an estimated incremental cost-effectiveness ratio of $23 600 per quality-adjusted life year gained. Although the cost-effectiveness ratio for stenting changed with variations in assumptions about the relative costs and restenosis rates, it remained less than $40 000 per qualityadjusted year of life gained-and thus was similar to many other accepted medical treatments-unless the stent angiographic restenosis rate was >23%, the angioplasty restenosis rate was <34%, or the cost of stenting (including vascular complications) exceeded that of conventional angioplasty by more than $3000. The alternative strategy of secondary stenting (initial angioplasty followed by stenting only for symptomatic restenosis) was estimated to be both less effective and less cost-effective than primary stenting over a wide range of plausible assumptions and thus does not appear to be costeffective when primary stenting is also an option.
Conclusions Decision-analytic modeling can be used to evaluate the potential cost-effectiveness of new coronary interventions. Our analysis suggests that despite its higher cost, elective coronary stenting may be a reasonably cost-effective treatment for selected patients with single-vessel coronary disease. Primary stenting is unlikely to be cost-effective for lesions with a low probability of restenosis (eg, <30%) or for patients for whom the cost of stenting is expected to be much higher than usual (eg, because of a high risk of vascular complications). Given the sensitivity of the cost-effectiveness ratios to even modest variations in the relative restenosis rates and cost estimates, future studies will be necessary to determine more precisely the cost-effectiveness of coronary stenting for specific patient and lesion subsets. (Circulation. 1994; 89:1859 -1874 Finally, during the first 6 months after successful PTCA or stenting, patients were at risk for angiographic restenosis (defined as a recurrence of a stenosis >50% diameter) that could potentially cause recurrent anginal symptoms. In our model, patients with symptomatic restenosis were assumed to require repeat revascularization (by either PTCA or coronary stenting) as specified by the particular revascularization strategy. In our baseline analysis, we assumed that patients with recurrent symptomatic restenosis would undergo a maximum of three percutaneous revascularization attempts before undergoing elective bypass surgery. The effect of varying this assumption was studied by sensitivity analysis. Patients who remained free from symptomatic restenosis at the end of a 6-month cycle (or who had undergone successful bypass surgery) were assumed to have been removed from the risk pool for short-term restenosis, and their remaining qualityadjusted life expectancy and treatment costs were estimated by use of a second model based on the natural history of treated single-vessel coronary disease (the Post-Revasc model). Data Sources for the Short-term Model
The probabilities of procedural success, abrupt closure requiring emergency stenting or bypass surgery, subacute thrombosis, procedural failure (without emergency bypass surgery), and death with each of the revascularization techniques were derived from a review of the literature published as of September 1993 (Table 1 , References 22 to 48). In the absence of published, head-to-head clinical trials, we attempted to minimize selection bias by including only studies that used techniques and definitions comparable to ours (see "Appendix").
Costs
See [CABG] ), or death. Patients with abrupt closure after angioplasty were assumed to undergo emergent coronary stenting with emergent bypass surgery if unsuccessful. C, Short-term (ie, 6-month) outcomes after initially successful percutaneous revascularization were evaluated according to the Initial Success subtree. Patients were at risk for subacute thrombosis for the first 14 days after successful PTCA or stenting. In addition, patients could experience restenosis over the ensuing 6-month cycle. The probabilities of each short-term outcome were determined according to the particular interventional strategy chosen. The terminal nodes of the Procedure and Initial Success subtrees (shaded rectangles) are states of the Post-Revasc Markov subtree (see Fig 2) . Multiplier for second proceduret (7, 23, (26) (27) (28) (29) (30) 41) 1.1 1.4 Multiplier for third procedure (30, 31, 42) 1.5 Probability of vascular complication (7, 24, 43, 44) When both the duration and quality of life are important, outcomes can be measured in quality-adjusted life years (QALYs).68 In this context, 1 year of life without angina or hospitalization is assumed to be a year of perfect health and is assigned a value of 1.0 QALY. Previous studies have demonstrated that patients are generally willing to "trade" 1 year of life with severe angina for 0.7 years of perfect life.5657 Thus, each year of life with significant angina is valued at 0.7 QALYs. No study has specifically examined the quality of life of patients with restenosis, but we assumed that patients with symptomatic restenosis would have a utility of 0.8 (QALY per year) -intermediate between that of mild (0.9) and severe (0.7) angina -during the period when restenosis was present. Thus, over a 6-month period, a patient who experienced symptomatic restenosis was assumed to have accrued only 0.4 QALY (ie, 0.5 yearsx0.8 QALY per year). In contrast, a patient without restenosis would have accrued 0.5 QALY (ie, 0.5 years x 1 QALY per year) during the same half-year period. To avoid errors arising from these assignments, these values were subjected to extensive sensitivity analysis. Patients with clinically silent restenosis were assumed to have a quality of life equal to those patients without restenosis. Finally, we adjusted quality-of-life measurements to account for the shortterm morbidity of vascular complications, subsequent nonfatal myocardial infarctions, and further revascularization procedures (Table 2) , basing these adjustments on the estimated duration of hospitalization and recuperation for each event.
Postrevascularization Model
Patients who survived our short-term model (either by remaining free from restenosis for a full 6-month cycle or by undergoing successful bypass surgery) entered the Post-Revasc model-a Markov (state-transition) model69 of life after successful angioplasty or bypass surgery (Fig 2) . Patients who did not require bypass surgery entered the model in the first health state (Stable Post-PTCA), and patients who underwent successful bypass surgery in the short-term model entered the Post-Revasc model in the second state (Stable Post-Bypass Surgery). During each cycle of the Post-Revasc model (assumed to last 6 months), patients could experience one of four possible events: they could die, suffer a myocardial infarction, undergo angioplasty, or undergo bypass surgery. In addition, during each cycle, patients who were asymptomatic could develop chronic stable angina (detail not shown in Fig 2) . As in the short-term model, patients who underwent angioplasty in the postrevascularization model could develop symptomatic restenosis requiring repeat angioplasty. Transition probabilities for each event were a function of the particular health state as well as the time interval after bypass surgery (Table 3 , References 70 to 87) and were derived from the published literature (see "Appendix"). All future costs and health benefits were discounted at 5% per year.
Analytic Method
For each strategy, we calculated the expected lifetime cost and quality-adjusted life expectancy, ranking the available strategies in order of increasing cost. Strategies with lower quality-adjusted life expectancies and higher costs than an available alternative were considered to be dominated by the remaining strategies and were excluded from further consideration. 88 For each of the remaining strategies (with higher expected costs but also higher quality-adjusted life expectancy), we calculated the incremental cost-effectiveness ratio by dividing any difference in cost by the difference in qualityadjusted life expectancy. All analyses were performed using the SMLTREE software package (James Hollenberg, MD, New York, NY).
Results

Primary Analysis
Under our baseline assumptions, our adjusted life expectancy unless the absolute reduction in the restenosis rate by stenting was <3%, the stent emergency bypass surgery rate was >5%, the stent thrombosis rate was >8%, or the probability of death from stent thrombosis was >24%. Our model estimated that quality-adjusted life expectancy would be greater for conventional angioplasty, however, if the disutility (ie, 1-utility) of life with a vascular complication were >0.20 -ie, more than twice the disutility of life with restenosis.
Sensitivity Analsis: Cost-eectiveness of Stenting
We also performed sensitivity analyses to determine which factors exerted the most influence on the costeffectiveness of stenting and how plausible variations in these assumptions would alter our results ( Table 5 ). The cost-effectiveness of coronary stenting was most sensitive to variations in the relative restenosis rates of stenting and conventional angioplasty. At any PTCA restenosis rate, the cost-effectiveness ratio for initial stenting became less favorable (ie, more $/QALY gained) as the stent restenosis rate increased (Fig 3) . For example, if the true restenosis rate for primary stenting were as high as 30% (compared with our baseline estimate of 20%), the cost-effectiveness ratio for initial stenting would increase to $120 000/QALY. Similarly, if the true angioplasty restenosis rate were only 30% (compared with our baseline estimate of 37%), stenting would also be less cost-effective, with a cost-effectiveness ratio of $82 100/QALY. Conversely, if the true angioplasty restenosis rate were higher than 43% (with a stent restenosis rate of 20%) or if the restenosis rate of stenting for de novo lesions were lower than 13% (with an angioplasty restenosis rate of 37%), initial coronary stenting would actually become the dominant strategy-that is, it would be both more effective and cost-saving compared with conventional angioplasty.
In a three-way sensitivity analysis, we explored the effect of simultaneous variations in the stent and PTCA restenosis rates on the cost-effectiveness of stenting at three different cost-effectiveness thresholds-$20 000/ QALY, $40 000/QALY, and $60 000/QALY. If one were willing to spend up to $40 000/QALY-similar to the cost-effectiveness of treating mild diastolic hypertension -stenting remained cost-effective unless the stent restenosis rate were >23% or the angioplasty restenosis rate were <34% (Fig 4) . In general, initial stenting remained cost-effective at this threshold level ($40 000/QALY) only if it reduced the PTCA restenosis rate by >14%. If one were willing to spend only up to $20 000/QALY, however, stenting would be cost-effective only if it reduced the PTCA restenosis rate by >18% to 20%.
The cost-effectiveness of coronary stenting also proved highly sensitive to variations in the cost of stenting. As the cost of stenting relative to PTCA increased, initial stenting became progressively less cost-effective in our model. For example, if the cost of initial hospitalization for stenting including any vascular complications were actually $8400 (ie, $3000 higher than the cost of PTCA), the cost-effectiveness ratio for stenting would increase to $40 000/QALY. Conversely, if the cost of stenting were reduced by $700 (to $7200, just $1800 more than conventional angioplasty), our model predicted that initial stenting would actually be less expensive than PTCA in the long run.
The cost-effectiveness of stenting was less sensitive to plausible variations in any other individual assumptions of the model. For example, the cost-effectiveness ratio for initial stenting remained <$40 000/QALY so long as the probability of emergency bypass surgery with angioplasty was >0.6% (Fig 5) . If, however, the probabilities of both abrupt closure and restenosis with conventional angioplasty were somewhat lower than our baseline estimates, the cost-effectiveness of stenting would change dramatically. For example, if PTCA had an emergency bypass surgery rate of only 0.7% and an angiographic restenosis rate of only 30%, the estimated cost-effectiveness ratio of stenting would rise to $102 000/QALY -much higher than most generally accepted medical programs.89
Similarly, the cost-effectiveness of stenting was relatively insensitive to plausible variations in the probabilities of procedure-related complications. As expected, as the probability of either subacute thrombosis or a major vascular complication after stenting was increased, coronary stenting became somewhat less costeffective in our model. Nonetheless, given our other baseline assumptions, the cost-effectiveness ratio for initial stenting remained <$40 000/QALY unless the probability of subacute stent thrombosis exceeded 3.5% (with a 13% vascular complication rate) or the probability of a major vascular complication exceeded 18% (with a 2% stent thrombosis rate) (Fig 6) .
The estimated cost-effectiveness ratio for coronary stenting remained between $10 000 and $40 000 per quality-adjusted year of life gained when any other individual assumption in either the short-term or the Post-Revasc model was varied (Table 5) . Furthermore, the strategy of initial angioplasty with subsequent 100 AC/AE indicates incremental cost-effectiveness of initial stenting compared with both alternative strategies (angioplasty only or secondary stenting); QALY, quality-adjusted life year; CABG, coronary artery bypass graft surgery; and PTCA, percutaneous transluminal coronary angioplasty.
*DS indicates dominant strategy; initial stenting both more effective and less expensive than the alternative strategies.
stenting only for symptomatic restenosis remained both less effective and less cost-effective than initial stenting over the full range of plausible values for each individual variable (including the restenosis rates and costs of angioplasty and stenting). Only when the restenosis rate for stenting restenotic lesions was <22% (ie, only 1.1 times the restenosis rate for de novo lesions) did the incremental cost-effectiveness ratio for secondary stenting become lower than that for primary stenting.
Mechanisms of the Long-term Benefits of Coronary Stenting
Coronary stenting may provide clinical benefit over conventional angioplasty by three potential mechanisms: (1) by reducing the incidence of severe dissection and abrupt closure, thereby avoiding emergency bypass surgery; (2) by reducing the incidence of restenosis; and (3) by eliminating elastic recoil as a cause of unsuccessful angioplasty. To determine the relative contributions of each of these mechanisms to the overall clinical benefit of stenting, we constructed separate models in which the benefits of stenting over conventional PTCA were alternately restricted to one of the three mechanisms. When the benefits of stenting were restricted to the prevention of abrupt closure, this mechanism accounted for only 9% of the overall improvement in quality-adjusted life expectancy predicted by our full model (Fig 7) . When the benefits of stenting were restricted to the reduction of restenosis, however, 88% of the full benefit of stenting was realized. The remaining 3% of the predicted benefits of stenting derived from the minor improvement in procedural success obtained by eliminating elastic recoil. Plot of a three-way sensitivity analysis varying the rates of stent thrombosis and major vascular complications as well as the threshold of acceptable cost-effectiveness. Points above each line represent those combinations of subacute thrombosis and vascular complication rates for which the incremental cost-effectiveness ratio for stenting exceeds the specified cost-effectiveness threshold, and points below each line represent combinations of restenosis rates for which the incremental cost-effectiveness ratio for stenting is below that threshold. The asterisk indicates the baseline values for this analysis (vascular complication rate, 13%; subacute thrombosis rate, 2%). QALY indicates quality-adjusted life year; PTCA, percutaneous transluminal coronary angioplasty. hemodialysis,91 treatment of mild hypertension with diuretics,92 and implantable defibrillator treatment for survivors of out-of-hospital cardiac arrest.9394 Conversely, cost-effectiveness ratios >$60 000/QALY are higher than those of most accepted treatments and are therefore generally regarded as unattractive.89 Thus, under our baseline assumptions, initial coronary stenting appears to have a cost-effectiveness ratio that is favorable compared with other widely practiced medical interventions.
It is important to recognize that the results of this analysis are sensitive to several critical assumptions of our model -mainly the relative restenosis rates for angioplasty and stenting. If the reduction in restenosis by stenting is less than we have assumed, coronary stenting would be significantly less cost-effective than is suggested by our model. For example, if one were willing to pay up to $40 000/QALY (similar to the cost-effectiveness of hemodialysis or treating mild hypertension), stenting would remain a cost-effective initial treatment only if the absolute difference in restenosis rates was 214% (Fig 4) . Recent randomized trials suggest that such a reduction in the PTCA restenosis rate by stenting may be feasible. 32 Conversely, our analysis suggests that regardless of the acceptable cost-effectiveness ratio, the strategy of secondary stenting is not cost-effective when initial stenting is also an option. Over a wide range of alternative assumptions, we found that secondary stenting was both less effective and less cost-effective than initial stenting (Table 4) . Thus, even if one were willing to pay the high cost of secondary stenting, greater overall health benefits could be achieved at a lower cost by practicing initial stenting instead.
Effect of Variations in the Cost of Stenting on Cost-effectiveness
Our analysis also demonstrates that the cost-effectiveness of coronary stenting is highly dependent on the cost of stenting relative to angioplasty. Consequently, it will be important to verify our cost estimates in a variety of patient populations and clinical settings -ideally in the form of a multicenter, randomized clinical trial. One factor that can clearly affect the cost of stenting is the overall incidence of vascular complications. Our previous study suggests that a major vascular complication increases the in-hospital cost of stenting by approximately $5000.10 In the present study, sensitivity analysis demonstrates that an increase in the rate of major vascular complications from 13% to 20% without a corresponding decrease in the subacute stent thrombosis rate would increase the cost-effectiveness ratio for stenting to $44 000/QALY. Since elderly and female patients appear to be at increased risk for vascular complications,4495 coronary stenting is likely to be less cost-effective in such high-risk patients unless the risks of abrupt closure and restenosis after conventional angioplasty are also increased in this population. Conversely, modest increases in the incidence of vascular complications might be acceptable if they are associated with a lower rate of stent thrombosis. Our analysis suggests that the cost-effectiveness ratio for stenting would be unchanged if more aggressive anticoagulation reduced the stent thrombosis rate by 1% while increasing the incidence of vascular complications by no more than 3% (Fig 6) .
Variations in the cost of stenting from different payer perspectives can also alter the apparent cost-effectiveness of stenting. Whereas our earlier study demonstrated that the true cost of stenting is 50% higher than that of conventional angioplasty (an absolute difference of $2500), other studies have found that hospital charges for stenting are 70% to 100% greater than charges for PTCA.9,12 If we use these charge values, the apparent cost-effectiveness ratio for initial coronary stenting would increase dramatically to $90 000 to $147 000/QALY. Whereas such ratios may be relevant to some third-party payers who actually pay charges, they cannot be compared directly with cost-effectiveness ratios established for other medical programs, which are generally based on costs. If the goal of the analysis is to facilitate efficient resource allocation within the overall health-care system, cost-effectiveness analysis based on actual resource costs is more appropriate.5960
Finally, this study demonstrates that it is unlikely that current stent technology will prove to be cost-saving compared with PTCA. Our model predicts that cost savings would occur only if the incremental cost of stenting over PTCA were <$1800 (ie, $700 below present levels) or if the stent restenosis rate were < 13%. Although neither of these thresholds appears to be attainable with current technology, they might be obtained with a nonthrombogenic stent (which would not require prolonged hospitalization for initiation of anticoagulation) or by use of collagen plugs at the vascular puncture site to reduce the incidence of expensive vascular complications. Alternatively, development of a stent coated with a potent antiproliferative agent might achieve the reduction in restenosis necessary to result in significant cost savings, despite an unchanged acute hospital cost. Importance of Lesion-Based Characteristics in Determining the Cost-effectiveness of Coronary Stenting By superimposing a specific and reasonable costeffectiveness threshold (ie, a societal "willingness-to-pay" for health benefits) on our model, sensitivity analysis can be used to identify the optimal revascularization strategy for any combination of abrupt closure and restenosis rates (Fig 5) . Although initial coronary stenting appears reasonably cost-effective under our baseline assumptions, our analysis demonstrates that stenting would be significantly less cost-effective if applied to patients whose probabilities of abrupt closure and restenosis with conventional angioplasty are both very low (eg, <3% and <30%, respectively). Con Our analysis has important implications for future clinical trials in interventional cardiology. Currently, such trials are designed to detect an arbitrary "clinically significant" reduction in the restenosis rate. However, our analysis suggests that for coronary stenting to be reasonably cost-effective, it must reduce angiographic restenosis by at least 14% compared with conventional angioplasty (eg, an absolute reduction from 37% to 23%). Smaller reductions in the rate of angiographic restenosis (on the order of 5% to 10%) might be biologically and clinically significant but are unlikely to be cost-effective given the additional cost of stenting. Decision-analytic models such as ours might thus be used to provide estimates of clinically and economically significant effects in the design of future randomized device trials.
Study Limitations
The 
Conclusions
This study demonstrates how decision-analytic techniques can be used to model the cost-effectiveness of alternative techniques for coronary intervention. In the case of coronary stenting, our analysis demonstrates that the major determinants of cost-effectiveness are the relative restenosis rates for angioplasty and stenting and the incremental cost of stenting. Using the best data currently available, our decision-analytic model suggests that despite its higher acute cost, coronary stenting may be a reasonably cost-effective initial treatment for patients with symptomatic single-vessel coronary disease. Conversely, the strategy of initial angioplasty followed by stenting only for symptomatic restenosis was estimated to be both less effective and less cost-effective than primary stenting over a wide range of plausible assumptions and thus does not appear to be costeffective when primary stenting is also an option.
When additional detailed results of randomized clinical trials and controlled observational studies become available in the future, they could be incorporated into our model to allow more precise definition of the cost-effectiveness of coronary stenting for specific types of patients and lesions. Given the sensitivity of the cost-effectiveness ratios to even modest variations in either the relative restenosis rates or the cost of stenting compared with PTCA, it is likely that these studies will demonstrate that primary coronary stenting is most cost-effective for lesions with a higher than usual likelihood of restenosis or abrupt closure and in patients with a relatively low probability of developing a vascular complication. Conversely, in patients for whom the risks of restenosis and abrupt closure with conventional angioplasty are both low (eg, <30% and <3%, respectively), the cost-effectiveness ratio for primary stenting is likely to be unfavorable. Although angioplasty is a relatively new technique, a large number of studies with 5-to 10-year follow-up suggest that average excess cardiac mortality after successful single-vessel angioplasty is 0.3% to 0.7% per year.20'5"70-7375 Studies of single-vessel bypass surgery compiled during the era of modern myocardial preservation and revascularization techniques suggest similar late cardiac mortality rates.4951'7747677 Agespecific, noncardiac mortality was assumed to be equal among treatment groups and was estimated from US life tables.103 (See Table 3 .)
Appendix
Late Cardiac Events After Single-Vessel Angioplasty Late event rates after successful angioplasty for single-vessel disease were derived from three major studies. Weintraub et a170 reported annual rates of myocardial infarction, repeat angioplasty, and bypass surgery over a 6-year follow-up period in 1492 patients with angiographically proven late patency after angioplasty. This patient population is comparable to those patients without restenosis who we assumed would enter the Post-Revasc model. Frierson et a172 reported the 5-year clinical follow-up of 537 patients treated with isolated LAD angioplasty, and Webb et al51 reported the 8-to 11-year follow-up of 143 patients who underwent successful angioplasty between 1978 and 1981. To eliminate events caused by short-term restenosis (which are incorporated in our shortterm model), we considered only events occurring after the first follow-up year in our calculation of event rates from these studies.
Late Cardiac Events After Single-Vessel Bypass Surgery
The reported rates of late angioplasty after successful single-vessel bypass surgery range from 0.5% to 1.8% per year.51"547',77,86 Several of these studies,54'77 however, include a large number of patients from the preangioplasty era and thus are likely to underestimate follow-up angioplasty rates. Studies that have examined the long-term follow-up of patients treated with single-vessel angioplasty or bypass surgery (because of failed PTCA) suggest that the relative risk of late PTCA after initially successful bypass surgery is 25% to 30% lower than that after initially successful angioplasty."5171
The reported incidence of late myocardial infarction after single-vessel bypass surgery ranges from 0.8% to 2.4% per year and appears to increase over time. 49,51"63'7',74-78,85 This increase is a result of graft failure, which accelerates 5 to 10 years after bypass surgery.04 We therefore constructed a Weibull model105 of the probability of nonfatal myocardial infarction after single-vessel bypass surgery to allow the annual probability of myocardial infarction to increase with time. To avoid extrapolating beyond the available data, we assumed that the annual probability of myocardial infarction remains constant beyond 15 years after bypass surgery. The rate of repeat bypass surgery after initial single-vessel bypass grafting also increases from 0.4% per year to 1.5% per year with increasing duration of follow-up.5"547"86 '87 We therefore constructed a second Weibull model to predict this rate.
